Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Shelby Barnett

Newcastle AuthorsTitleYearFull text
Dr Shelby Barnett
Professor Gareth Veal
Development and validation of a LC-MS/MS method for the quantification of novel therapeutic TT-478, a selective adenosine receptor 2B antagonist, for a phase I/II clinical trial2025
Dr Andrew Brandon
Dr Shelby Barnett
Professor Gareth Veal
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice2025
Dr Shelby Barnett
Professor Gareth Veal
A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups2024
Professor Gareth Veal
Dr Shelby Barnett
Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom2024
Dr Shelby Barnett
Dr Martin Galler
Dr David Jamieson
Professor Gareth Veal
Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report2023
Dr Shelby Barnett
Professor Deborah Tweddle
Professor Gareth Veal
Generation of evidence-based carboplatin dosing guidelines for neonates and infants2023
Dr Shelby Barnett
Professor Gareth Veal
Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk2023
Julie Errington
Dr Shelby Barnett
Professor Gareth Veal
Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma2023
Dr Shelby Barnett
Professor Gareth Veal
A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children2022
Dr Shelby Barnett
Dr Vickyanne Carruthers
Professor Deborah Tweddle
Professor Gareth Veal
Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance2022
Dr Vickyanne Carruthers
Dr Shelby Barnett
Dr Tasnim Arif
Professor Gareth Veal
Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series2022
Dr Shelby Barnett
Professor Gareth Veal
Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations2022
Dr Shelby Barnett
Professor Deborah Tweddle
Professor Gareth Veal
Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients2022
Dr Shelby Barnett
Professor Gareth Veal
Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom2021
Dr Shelby Barnett
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability2021
12